Focal Adhesion Kinase: Can Adding Fibroblasts and C-X-C Chemokine Help With Suppression? Arsen Osipov - Synopsis below extracted from the video transcript.
Recent Posts
Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area Anthony Tolcher MD - Synopsis below extracted from the video transcript.
CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel - Synopsis below extracted from the video transcript.
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Connor Johnson MD - Synopsis below extracted from the video transcript.
"Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study" by Dr. Connor Johnson provides an overview of the use of CAR-T cell therapy in treating patients with B-cell malignancies. CAR-T cell therapy involves re-engineering a patient's own immune cells to recognize and attack cancer cells. Dr. Johnson discusses his experience treating patients with CAR-T cell therapy and the results of a longitudinal study that followed patients over a period of several years.
DCISionRT: Examining the Effectiveness of Adjuvant Endocrine Therapy for Breast Cancer Patients After BCS Chirag Shah MD
- Synopsis below extracted from the video transcript.
Platinum Chemotherapy: vs. Temozolomide/Capecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD - Synopsis below extracted from the video transcript.
Poster discussed by Anna Odell, City of Hope - Friends of Cancer Research - Dr. Monty Pal served as a guide and advisory mentor.
In this poster, Anna Odell discusses the studies for treating RCC. "Evaluation of eligibility criteria in contemporary renal cell cancer trials based on ASCO-FCR recommendations.". She emphasizes the need of carefully choosing patients for clinical trials based on the specific molecular and genetic qualities they possess, and she describes the many types of RCC, including papillary and clear cell RCC.
Poster discussed by Ishann Sehgal, City of Hope - Friends of Cancer Research - Dr. Monty Pal served as a guide and advisory mentor.
Ishann Sehgal addresses the eligibility requirements for clinical trials involving renal cell carcinoma (RCC) in this video. He also covers the advancements that ASCO and FCR have made in the treatment of RCC.
According to Ishann, the qualifying standards for RCC clinical research have traditionally been quite stringent. This has the potential to restrict patient involvement and affect the findings of the study. Both the ASCO and the FCR have revised their qualifying requirements in order to accommodate a greater number of patients.
